pt2c00076_si_001.pdf (861.07 kB)
Characterization of Dual-Acting A3 Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gαi3 and GαoA Isoprotein Activation
journal contributionposted on 2022-07-15, 18:04 authored by Courtney L. Fisher, Lucas B. Fallot, Tina C. Wan, Robert F. Keyes, R. Rama Suresh, Amy C. Rothwell, Zhan-Guo Gao, John D. McCorvy, Brian C. Smith, Kenneth A. Jacobson, John A. Auchampach
The A3 adenosine receptor (A3AR) is a promising therapeutic target for inflammatory diseases, cancer, and chronic neuropathic pain, with agonists already in advanced clinical trials. Here we report an in-depth comparison of the pharmacological properties and structure–activity relationships of existing and expanded compound libraries of 2-substituted 1H-imidazo[4,5-c]quinolin-4-amine and 4-amino-substituted quinoline derivatives that function as A3AR positive allosteric modulators (PAMs). We also show that our lead compound from each series enhances adenosine-induced A3AR signaling preferentially toward activation of Gαi3 and GαoA isoproteins, which are coexpressed with the A3AR in immune cells and spinal cord neurons. Finally, utilizing an extracellular/intracellular chimeric A3AR approach composed of sequences from a responding (human) and a nonresponding (mouse) species, we provide evidence in support of the idea that the imidazoquinolin-4-amine class of PAMs variably interacts dually with the orthosteric ligand binding site as well as with a separate allosteric site located within the inner/intracellular regions of the receptor. This study has advanced both structural and pharmacological understanding of these two classes of A3AR PAMs, which includes leads for future pharmaceutical development.
spinal cord neuronspromising therapeutic targetfuture pharmaceutical developmentchronic neuropathic painseries enhances adenosinepreferentially enhance adenosinesubstituted quinoline derivativesexpanded compound librariesoa subi3 sub3 subar approach composedadvanced clinical trialsh c substituted 1lead compoundadenosine receptortwo classesprovide evidencepharmacological understandingpharmacological propertiespams ).isoprotein activationintracellular regionsintracellular chimericinflammatory diseasesincludes leadsimmune cellsdepth comparisonar pamsalso showagonists already>] quinolin5 -<